US Pharma MarketingGSK drug Jemperli met the main goal of a pivotal Phase 2 test in patients with a rare type of rectal cancer, paving the way for regulatory submissions. This antibody drug has already received a voucher to speed up its review under a new FDA pilot program. Toggle Search Close navigation News Health Tech BioPharma Devices & Diagnostics Consumer / Employer Contributors MedCity Influencers Events Bullseye INVEST Digital Health Podcasts Research Spotlight Payer Challenges and Opportunities Newsletters Newsletter Signup Send Tips Webinars eBooks Twitter Facebook TikTok YouTube LinkedIn RSS Subscribe via email Search for: Search BioPharma, Pharma GSK Eyes FDA…
GSK drug Jemperli met the main goal of a pivotal Phase 2 test in patients with a rare type of rectal cancer, paving the way for regulatory submissions. This antibody drug has already received a voucher to speed up its review under a new FDA pilot program.
The post GSK Eyes FDA Filing After Immunotherapy Succeeds in Key Rectal Cancer Study appeared first on MedCity News.
Source: MedCity News